NL-OMON22104招募中不适用
BONE MINERAL DENSITY IN PROSTATECANCER PATIENTS TREATED WITHANDROGEN DEPRIVATION THERAPY
SFG, Rotterdam, The Netherlands0 个研究点目标入组 51 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 51
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Age >18 years
- •1. Indication for ADT as treatment for nonmetastatic prostate cancer according to the
- •Bolla schedule;
排除标准
- •Pre-existing indication for osteoporosis treatment, i.e. before the baseline DEXA
研究者
相似试验
招募中
不适用
BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPYosteoporosisbone loss1001329610038364NL-OMON37103Sint Franciscus Gasthuis51
尚未招募
1 期
STUDY OF ASSESSING RISK OF DIABETES MELLITUS IN DEVELOPING OSTEOPOROSISCTRI/2019/06/019562ANUPA JOH
已完成
不适用
Periprosthetic bone mineral density (BMD) around two different stems in total hip arthroplastyOsteoarthritis of the hipMusculoskeletal DiseasesOsteoarthritisISRCTN54967983German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany)50
已完成
不适用
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPCBone MetastasisMetastatic Prostate CancerNCT01062503University Health Network, Toronto48
招募中
不适用
Evaluation of bone mineral density and bone metabolism during treatment with the januskinaseinhibitor upadacitinib in patients with rheumatoid arthritisDRKS00021182Campus Kerckhoff der Jusuts-Liebig-Universität Gießen, Abteilung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin60